Increasingly, genome-wide testing is being undertaken for many different clinical indications, and this may identify variants in the DMD gene in patients where a clinical diagnosis of dystrophinopathy has not been considered or suspected. This evidence concerns the gene DMD and neuromuscular disease caused by qualitative or quantitative defects of dystrophin.